Market Performance Overview
- Mach (M7T.AX)
- Closing price: AUD 0.25 (unchanged)
- Trading volume in the last 24 hours: AUD 2,400
- Market capitalization: AUD 56.4 million
- Shares outstanding: 235 million
- 200‑day simple moving average: AUD 0.30
- 52‑week high: AUD 0.68 (01 May 2026)
- 52‑week low: AUD 0.21 (15 Oct 2026)
Comparative Performance (Last 24 Hours)
| Stock | Symbol | Price (AUD) | % Change | Market Cap (AUD M) | Additional Notes |
|---|---|---|---|---|---|
| Hammer Metals | HMX.AX | 0.08 | –2.7 % | 64.3 | — |
| Verbrec | VBC.AX | 0.22 | –4.35 % | 67.4 | P/E ratio 22.5 |
| Neurizon Therapeutics | NUZ.AX | 0.09 | +3.8 % | 64.9 | AGM on 25 Nov 2026; detailed agenda |
| Vhm | VHM.AX | 0.22 | 0 % | 65.5 | — |
| Ardea | ARL.AX | 0.31 | 0 % | 67.0 | AGM on 27 Nov 2026; key resolutions listed |
Upcoming Corporate Actions
Neurizon Therapeutics (NUZ.AX)
- Annual General Meeting: 25 November 2026
- Location: Hybrid session – Gilbert + Tobin, Melbourne and online video‑conferencing
- Key Resolutions:
- Adoption of the remuneration report
- Election of Dr. Ross Murdoch to the board
- Approval of 1.5 million options for Dr. Murdoch under the equity incentive plan
- Approval of a convertible‑note purchase from Obsidian Global GP
- Special resolution to increase the equity‑issue limit from 15 % to 25 % for the next 12 months
- Documentation: Notice of meeting, explanatory statement, 2026 Annual Report (financial statements, directors’ and remuneration reports, auditor comments) available electronically.
- Shareholder Engagement: Encouragement of early proxy submission; agenda includes discussion of ongoing trials and funding strategy.
Ardea Resources Ltd. (ARL.AX)
- Annual General Meeting: 27 November 2026
- Key Resolutions:
- Re‑election of Director Hugh Keller
- Issuance of ordinary shares to Directors Keller and Joe Kaderavek to cover part of their 2027 director fees
- Grant of performance rights to CEO Dr. Andrew Tong and non‑executive directors for long‑term incentive plans
- Special resolution to approve a 10 % placement facility under ASX Listing Rule 7.1A, extending equity issuance capacity beyond the usual placement limit
- Purpose: Align director remuneration with shareholder interests while preserving cash for operational and development activities.
Company Background – Mach7 Technologies Ltd. (M7T.AX)
Mach7 Technologies is an Australian health‑care technology company listed on the ASX All Markets. The firm specializes in developing software solutions for the health sector, offering products such as an Enterprise Imaging Platform, Vendor Neutral Archive, Communication Workflow Engine, and Managed Data Solutions. The company is headquartered in Port Melbourne and went public on 30 November 2005.
